Diclofenac (Panamor, A-lennon Diclofenac, Pharmflam, Dicloflam Gt, Fortfen /Inspuiting, Noriphen, Panamor Sr, Fortfen, Infla-ban Sr, Diclo-flam Blackcurrant, Panamor Eye, Disflam ( ), Panamor At, Fortfen Simple Regimen)
Diclofenac
Pharmacare limited û woodmead
Registration
- Applicant
- Pharmacare limited û woodmead
- Registrations
- 26
- Schedule source
- SAHPRA documentation
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Panamor suppositories - 12,5 EACH SUPPOSITORY CONTAINS DICLOFENAC SODIUM 12,5 mg | - 12,5Suppositories | 27012127/3.1/0121 | Registered | Not determined | None |
| A-lennon diclofenac 75 MG injection EACH 3 ml AMPOULE CONTAINS DICLOFENAC SODIUM 75 mg | 75 mgInjection | 27029327/3.1/0293 | Cancelled | Not determined | None |
| A-lennon diclofenac 25 MG EACH TABLET CONTAINS DICLOFENAC SODIUM 25 mg | 25 mg | 27031427/3.1/0314 | Registered | Not determined | None |
| A-lennon diclofenac 50 MG tablet EACH TABLET CONTAINS DICLOFENAC SODIUM 50 mg | 50 mgTablet | 27031527/3.1/0315 | Registered | Not determined | None |
| Pharmflam - 25 EACH TABLET CONTAINS DICLOFENAC SODIUM 25 mg | - 25 | 27041727/3.1/0417 | Cancelled | Not determined | None |
| Dicloflam gt 50 EACH TABLET CONTAINS DICLOFENAC SODIUM 50 mg | 50 | 27041827/3.1/418 | Registered | Not determined | None |
| Pharmflam - 75 EACH 3 ml AMPOULE CONTAINS DICLOFENAC SODIUM 75 mg | - 75 | 27041927/3.1/419 | Cancelled | Not determined | None |
| Fortfen injection/inspuiting EACH 3 ml SOLUTION CONTAINS DICLOFENAC SODIUM 75,0 mg | Injection/inspuiting | 27054427/3.1/0544 | Cancelled | Not determined | None |
| Noriphen 25 mg/ml injections EACH 3 ml SOLUTION CONTAINS DICLOFENAC SODIUM 75 mg | 25 mg/mlInjections | 28020428/3.1/0204 | Cancelled | Not determined | None |
| Panamor - 75 sr tablets EACH TABLET CONTAINS : DICLOFENAC SODIUM 75 mg | - 75Tablets | 29012129/3.1/0121 | Registered | Not determined | None |
| Panamor - 100 sr tablets EACH TABLET CONTAINS DICLOFENAC SODIUM 100 mg | - 100Tablets | 29012229/3.1/0122 | Registered | Not determined | None |
| A-lennon diclofenac 100 MG suppository EACH SUPPOSITORY CONTAINS DICLOFENAC SODIUM 100 mg | 100 mgSuppository | 29025729/3.1/0257 | Registered | Not determined | None |
| Pharmflam 100 MG suppositories EACH SUPPOSITORY CONTAINS DICLOFENAC SODIUM 100 mg | 100 mgSuppositories | 29025829/3.1/0258 | Cancelled | Not determined | None |
| Fortfen gel EACH 100 g GEL CONTAINS DICLOFENAC DIETHYLAMMONIUM EQUIVALENT TO DICLOFENAC SODIUM 1 g | Gel | 29071929/3.1/0719 | Cancelled | Not determined | None |
| Infla-ban sr EACH TABLET CONTAINS DICLOFENAC SODIUM 100 mg | Not listed | 29074629/3.1/0746 | Cancelled | Not determined | None |
| Panamor patch EACH PLASTER CONTAINS DICLOFENAC EPOLAMINE EQUIVALENT TO DICLOFENAC 0,130 g | Patch | 33009133/3.1/0091 | Registered | Not determined | None |
| Diclo-flam blackcurrant EACH TABLET CONTAINS DICLOFENAC SODIUM 50,0 mg | 50.0 mgDispersible tablets | 37060737/3.1/0607Approved 28 November 2021 | Registered | Not determined | PIPIL |
| Panamor eye drops EACH 1,0 ml SOLUTION CONTAINS DICLOFENAC 1,0 mg | 1 mg/mlOphthalmic solution. | 45068645/15.4/0686Approved 2 November 2021 | Registered | S3 | PIPIL |
| Panamor 50 MG dispersible tablet EACH TABLET CONTAINS DICLOFENAC 46,5 mg | 50 mgDispersible tablet | A380383A38/3.1/0383Approved 24 October 2025 | Registered | S2 | PIPIL |
| Disflam (dispersible tablet) EACH TABLET CONTAINS DICLOFENAC 46,5 mg | (Dispersible tablet) | A380390A38/3.1/0390 | Registered | Not determined | None |
| Panamor - 25 EACH TABLET CONTAINS DICLOFENAC SODIUM 25 MG | 25 mgFilm-coated tablets | R0049R/3.1/49Approved 29 November 2021 | Registered | S2 | PIPIL |
| Panamor at - 50 EACH TABLET CONTAINS DICLOFENAC SODIUM 50 MG | 50 mgFilm-coated tablets | R0050R/3.1/50Approved 28 November 2021 | Registered | S2 | PIPIL |
| Panamor - 75 injection EACH 3 ml AMPOULE CONTAINS DICLOFENAC SODIUM 75 ml | - 75Injection | W0052W/3.1/52 | Registered | Not determined | None |
| Fortfen 100 simple regimen EACH CAPSULE CONTAINS DICLOFENAC SODIUM 100,0 mg | 100 | Y0189Y/3.1/189 | Cancelled | Not determined | None |
| Panamor suppositories EACH SUPPOSITORY CONTAINS DICLOFENAC SODIUM 100 mg | Suppositories | Y0395Y/3.1/395 | Registered | Not determined | None |
| Panamor suppositories - 25 EACH SUPPOSITORY CONTAINS DICLOFENAC SODIUM 25,0 mg | - 25Suppositories | Z0172Z/3.1/172 | Registered | Not determined | None |
Regulatory status
Where S3 sits on the scale
Needs a doctor's prescription, dispensed by a pharmacist.
Schedule 3 medicines can only be sold on a prescription from an authorised prescriber, such as a doctor or dentist. A pharmacist dispenses the medicine once they have the written prescription, or a verbal instruction from a prescriber they know. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.
Schedule S3, read from the product's PI-PIL leaflet.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Diclofenac
S3: Diclofenac
- except when intended for application to the skin and containing 1 % m/m or less of diclofenac subject to a maximum pack size of 50 grams; (S0)
- except when intended for application to the skin and containing more than 1 % m/m of diclofenac; (S1)
- except when intended for the emergency treatment of acute gout attacks, subject to a maximum daily dose of 150 mg for a maximum treatment period of 3 days; (S2)
- except when intended for human use only in the treatment of fever or mild to moderate pain of inflammatory origin, or for the treatment of post-traumatic conditions subject to a maximum daily dose of 75 mg for a maximum treatment period of 5 days. (S2)
Consolidated Schedules 06 July 2026, lines 3415 to 3427
S2: Diclofenac
- when intended for the emergency treatment of acute gout attacks, subject to a maximum daily dose of 150 mg for a maximum treatment period of 3 days; (S3)
- when intended for human use only in the treatment of fever or mild to moderate pain of inflammatory origin, or for the treatment of post-traumatic conditions, subject to a maximum daily dose of 75 mg for a maximum treatment period of 5 days;
- except when intended for application to the skin and containing 1 % m/m or less of diclofenac subject to a maximum pack size of 50 grams; (S0)
- except when intended for application to the skin and containing more than 1 % m/m of diclofenac; (S1)
- except when intended for veterinary use. (S3)
Consolidated Schedules 06 July 2026, lines 1807 to 1821
S1: Diclofenac
- when intended for application to the skin and containing more than 1 % m/m of diclofenac; (S3)
- except when intended for application to the skin and containing 1 % m/m or less of diclofenac subject to a maximum pack size of 50 grams; (S0)
- except when intended for the emergency treatment of acute gout attacks, subject to a maximum daily dose of 150 mg for a maximum treatment period of 3 days; (S2)
- except when intended for human use only in the treatment of fever or mild to moderate pain of inflammatory origin, or for the treatment of post-traumatic conditions, subject to a maximum daily dose of 75 mg for a maximum treatment period of 5 day; (S2)
- except when intended for veterinary use. (S3)
Consolidated Schedules 06 July 2026, lines 365 to 379
Pharmacological class: Others. (class 15.4)
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
2-[2-(2,6-Dichloroanilino)phenyl]acetic acid
Drag to rotate. Structure from PubChem CID 3033.
SAHPRA documents
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.